Evidence map›Paper›PMID 40774695›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2026

[

Nathalie L Albert, Emeline Tabouret, Emilie Le Rhun, Felix Sahm, Julia Furtner, Joerg-Christian Tonn, Christian Alfano, José Pais Silva, Anne-Sophie Govaerts, Thierry Gorlia and 5 more

Abstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Molecular Brain Tumor Imaging Beyond [AJR. American journal of roentgenology · 2026
    Review
  2. Review
  3. Review
  4. Combined SSTR2-targeted Analogue withFrontiers in oncology · 2026
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Nathalie L AlbertDepartment of Nuclear Medicine, LMU Hospital, Ludwig Maximilians University, Munich, Germany; nathalie.albert@med.uni-muenchen.de.
Emeline TabouretAPHM, Aix-Marseille University, CNRS, INP, Marseille, France.
Emilie Le RhunDepartment of Medical Oncology and Hematology, University Hospital and University of Zurich, Zurich, Switzerland.
Felix SahmDepartment of Neuropathology, University Hospital Heidelberg and Clinical Cooperation Unit Neuropathology, DKFZ and DKTK, Heidelberg, Germany.
Julia FurtnerResearch Center for Medical Image Analysis and Artificial Intelligence, Faculty of Medicine and Dentistry, Danube Private University, Krems, Austria.
Joerg-Christian TonnDepartment of Neurosurgery, LMU Hospital, Ludwig Maximilians University, Munich, Germany.
Christian AlfanoEORTC Headquarters Team, Brussels, Belgium.
José Pais SilvaEORTC Headquarters Team, Brussels, Belgium.
Anne-Sophie GovaertsEORTC Headquarters Team, Brussels, Belgium.
Thierry GorliaEORTC Headquarters Team, Brussels, Belgium.
Osvaldo MiranteAdvanced Accelerator Applications, Geneva, Switzerland.
Giuseppe MinnitiDepartment of Radiologic Sciences, Oncology and Anatomical Pathology, Policlinico Umberto I, Sapienza University, Rome, Italy.
Michael WellerDepartment of Neurology, University Hospital and University of Zurich, Zurich, Switzerland; and.
Matthias Preusser
European Organisation for Research and Treatment of Cancer Brain Tumor Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There are no established treatment options for patients with meningioma recurring after surgery and radiotherapy. Somatostatin receptor type 2 (SSTR2) is highly expressed in meningiomas, and SSTR2-targeting radionuclide therapy with [

Indexed as

Meningeal NeoplasmsMeningiomaNeoplasm Recurrence, LocalOctreotideOrganometallic CompoundsAdultClinical Trials, Phase II as TopicFemaleHumansMaleRandomized Controlled Trials as TopicReceptors, SomatostatinRecurrencelutetium Lu 177 dotatateOctreotideOrganometallic CompoundsReceptors, Somatostatin[177Lu]Lu-DOTATATEclinical trialmeningiomaradiopharmaceutical therapytheranostic

Identifiers

PMID40774695
PMCPMC12766886

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.